The stock of Intra-Cellular Therapies Inc (NASDAQ:ITCI) is a huge mover today! About 261,570 shares traded hands. Intra-Cellular Therapies Inc (NASDAQ:ITCI) has declined 63.15% since April 18, 2016 and is downtrending. It has underperformed by 67.58% the S&P500.
The move comes after 8 months positive chart setup for the $608.99 million company. It was reported on Nov, 18 by Barchart.com. We have $22.58 PT which if reached, will make NASDAQ:ITCI worth $377.57M more.
Intra-Cellular Therapies Inc (NASDAQ:ITCI) Ratings Coverage
Out of 8 analysts covering Intra-Cellular Therapies (NASDAQ:ITCI), 6 rate it a “Buy”, 0 “Sell”, while 2 “Hold”. This means 75% are positive. Intra-Cellular Therapies has been the topic of 15 analyst reports since August 6, 2015 according to StockzIntelligence Inc. The rating was initiated by Piper Jaffray on Thursday, June 2 with “Overweight”. The rating was upgraded by Zacks to “Sell” on Friday, August 7. As per Friday, November 6, the company rating was maintained by RBC Capital Markets. SunTrust downgraded the shares of ITCI in a report on Thursday, September 29 to “Neutral” rating. The rating was maintained by JMP Securities with “Market Outperform” on Wednesday, March 9. The stock has “Buy” rating given by Guggenheim on Thursday, September 17. JMP Securities downgraded the stock to “Market Perform” rating in Thursday, September 29 report.
According to Zacks Investment Research, “Intra-Cellular Therapies Inc. is a biopharmaceutical company. The company develops drugs for the treatment of neuropsychiatric and neurologic diseases and other disorders of the central nervous system. Its product candidates include ITI-007, ITI-002 and ITI-009 which is in clinical trials. Intra-Cellular Therapies Inc. is headquartered in New York.”
Insitutional Activity: The institutional sentiment decreased to 0.94 in Q2 2016. Its down 0.77, from 1.71 in 2016Q1. The ratio turned negative, as 17 funds sold all Intra-Cellular Therapies Inc shares owned while 28 reduced positions. 23 funds bought stakes while 54 increased positions. They now own 30.01 million shares or 2.84% more from 29.18 million shares in 2016Q1.
Aqr Capital Limited Liability has 0% invested in the company for 17,162 shares. Us Bancorp De, a Minnesota-based fund reported 814 shares. Voya Invest Mngmt Limited has 14,573 shares for 0% of their US portfolio. The Connecticut-based Cubist Systematic Strategies Ltd Llc has invested 0% in Intra-Cellular Therapies Inc (NASDAQ:ITCI). Timessquare Capital Management Lc has 1.62M shares for 0.42% of their US portfolio. Adage Cap Prns Grp Incorporated Ltd Liability holds 0.12% or 1.10 million shares in its portfolio. The Missouri-based Atwood & Palmer has invested 0% in Intra-Cellular Therapies Inc (NASDAQ:ITCI). Frontier Limited Liability Corporation reported 81,999 shares or 0.03% of all its holdings. Blackrock Advisors Ltd holds 0.05% of its portfolio in Intra-Cellular Therapies Inc (NASDAQ:ITCI) for 1.26 million shares. Dubuque Bank & Trust has 0% invested in the company for 250 shares. Moreover, State Of New Jersey Common Pension Fund D has 0.01% invested in Intra-Cellular Therapies Inc (NASDAQ:ITCI) for 62,500 shares. The Connecticut-based Columbus Circle has invested 0.21% in Intra-Cellular Therapies Inc (NASDAQ:ITCI). Wexford L P has 37,994 shares for 0.26% of their US portfolio. Jpmorgan Chase & has invested 0% of its portfolio in Intra-Cellular Therapies Inc (NASDAQ:ITCI). Cupps Capital Ltd Limited Liability Company, a Illinois-based fund reported 51,995 shares.
Insider Transactions: Since November 14, 2016, the stock had 3 insider purchases, and 0 selling transactions for $1.48 million net activity. 34,000 shares were bought by Alafi Christopher D, worth $492,969. ALAFI CAPITAL CO LLC had bought 34,000 shares worth $492,969. Shares for $492,969 were bought by ALAFI MOSHE.
More recent Intra-Cellular Therapies Inc (NASDAQ:ITCI) news were published by: Fool.com which released: “Why Intra-Cellular Therapies Inc. Is Crashing Today” on September 29, 2016. Also Fool.com published the news titled: “Why Intra-Cellular Therapies Inc. Stock Rocketed 206% Higher In 2015” on January 14, 2016. Fool.com‘s news article titled: “Why Intra-Cellular Therapies Inc Stock Jump 21.4% in April” with publication date: May 07, 2016 was also an interesting one.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.